436 related articles for article (PubMed ID: 36232398)
1. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.
Kalkusova K; Smite S; Darras E; Taborska P; Stakheev D; Vannucci L; Bartunkova J; Smrz D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232398
[TBL] [Abstract][Full Text] [Related]
2. Mast cells as targets for immunotherapy of solid tumors.
Oldford SA; Marshall JS
Mol Immunol; 2015 Jan; 63(1):113-24. PubMed ID: 24698842
[TBL] [Abstract][Full Text] [Related]
3. Role of mast cells activation in the tumor immune microenvironment and immunotherapy of cancers.
Guo X; Sun M; Yang P; Meng X; Liu R
Eur J Pharmacol; 2023 Dec; 960():176103. PubMed ID: 37852570
[TBL] [Abstract][Full Text] [Related]
4. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
5. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
6. Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.
Li M; Zhong X; Du F; Wu X; Li M; Chen Y; Zhao Y; Shen J; Yang Z; Xiao Z
J Clin Pharmacol; 2022 Sep; 62(9):1059-1078. PubMed ID: 35303368
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
8. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
9. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL; Dos Santos ALS; Nunes NCC; de Moraes Lino da Silva F; Ferreira CGM; de Melo AC
Cancer Chemother Pharmacol; 2019 Aug; 84(2):227-240. PubMed ID: 31240384
[TBL] [Abstract][Full Text] [Related]
12. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
13. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
Ahn R; Ursini-Siegel J
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
[TBL] [Abstract][Full Text] [Related]
14. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
Khosravi N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Shahgoli VK; Hemmat N; Safarzadeh E; Baradaran B
Life Sci; 2020 Sep; 256():118005. PubMed ID: 32593711
[TBL] [Abstract][Full Text] [Related]
16. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
19. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
20. The influence of microenvironment on tumor immunotherapy.
Zhang J; Shi Z; Xu X; Yu Z; Mi J
FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
